KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Share-based Compensation (2018 - 2025)

Amneal Pharmaceuticals (AMRX) has 8 years of Share-based Compensation data on record, last reported at $8.2 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 13.76% year-over-year to $8.2 million; the TTM value through Dec 2025 reached $32.0 million, up 15.07%, while the annual FY2025 figure was $32.0 million, 15.07% up from the prior year.
  • Share-based Compensation reached $8.2 million in Q4 2025 per AMRX's latest filing, roughly flat from $8.2 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $8.3 million in Q2 2025 and bottomed at $5.3 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $7.3 million, with a median of $7.6 million recorded in 2021.
  • Peak YoY movement for Share-based Compensation: soared 51.31% in 2022, then dropped 23.71% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $7.7 million in 2021, then grew by 1.15% to $7.8 million in 2022, then decreased by 23.71% to $6.0 million in 2023, then rose by 20.69% to $7.2 million in 2024, then increased by 13.76% to $8.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $8.2 million in Q4 2025, $8.2 million in Q3 2025, and $8.3 million in Q2 2025.